Advertisement Press Releases Archive - Page 5 of 233 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Pressreleases

Search

  • 28 May 2024
    Gerresheimer Partners with RxCap to Offer Connected Adherence Solutions

    Gerresheimer Partners with RxCap to Offer Connected Adherence Solutions

    By Nat Schaefer

    Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has entered into a partnership with the US digital health company RxCap and acquired a minority stake. Under the terms of the agreement, Gerresheimer's subsidiary Centor will receive the exclusive distribution rights for pharmacies in the US for adherence solutions by RxCap, consisting of connected prescription vial closure devices and complementary cloud-based software. Centor is the US market leader in prescription vials and is uniquely positioned to enable smart adherence solutions through existing pharmacy workflows.

  • 28 May 2024
    Gerresheimer Makes Solid Start to the Financial Year 2024

    Gerresheimer Makes Solid Start to the Financial Year 2024

    By Nat Schaefer

    Gerresheimer, an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries, continued its profitable growth trajectory in the first quarter of 2024 with organic revenue growth of 2.8% and an organic increase in adjusted EBITDA of 5.9%. This positive development was fueled primarily by the performance of the Plastics & Devices Division. Revenues came to € 466.1m (Q1 2023: € 457.8m), with adjusted EBITDA standing at €80.9m (Q1 2023: €78.0m). The adjusted EBITDA margin improved organically by 50 basis points to 17.3% year on year (Q1 2023: 16.8%).

  • 09 Apr 2024
    Gerresheimer Performance Levels Simplify Choice of Optimum Solution

    Gerresheimer Performance Levels Simplify Choice of Optimum Solution

    By Nat Schaefer

    Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, presents its new performance levels for injection vials, syringes, cartridges and ampoules. Within the relevant product category, customers can choose from three performance levels: Gx Value, Gx Advance and Gx Elite. The new structure makes it easier to select the right product platform according to the requirements for the pharmaceutical active agent or area of application. Gx Elite products offer the highest performance and are especially suitable for innovative biopharmaceutical products.

  • 06 Mar 2024
  • 23 Feb 2024
    Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023

    Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023

    By Nat Schaefer

    Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, decisively continued on its profitable growth course in the financial year 2023 with an organic revenue growth of 10.4% and a strong adjusted EBITDA growth of 17.5%. Revenues reached €1.99bn (2022: €1.82bn), the adjusted EBITDA €404.5m (2022: €354.2m).

  • 19 Feb 2024
  • 11 Jan 2024
    Gerresheimer at Pharmapack 2024: Innovative Solutions and Expert Presentations

    Gerresheimer at Pharmapack 2024: Innovative Solutions and Expert Presentations

    By Nat Schaefer

    Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industry, will present its comprehensive portfolio of containment solutions, drug delivery systems and digital solutions in areas such as therapy support at this year’s Pharmapack. The company’s presence at the trade fair will focus on specialised primary packaging solutions for sensitive innovative drugs such as biopharmaceuticals, including cell and gene therapy products — from COP injection vials for cryogenic temperatures through to medication pumps.

  • 09 Jan 2024
    Gerresheimer and Aptar Digital Health Collaborate to Develop Integrated Solution for Cancer Therapy

    Gerresheimer and Aptar Digital Health Collaborate to Develop Integrated Solution for Cancer Therapy

    By Nat Schaefer

    Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, and Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programmes (PSPs) and disease management solutions, collaborate to develop an integrated solution for cancer therapy management. As part of this collaboration, the Gx SensAir on-body drug delivery device will be connected to Aptar Digital Health's software-as-a-medical device platform to improve the treatment experience and outcomes of cancer patients.

  • 28 Nov 2023
    Gerresheimer: Green Electricity from Wind for German Production Sites

    Gerresheimer: Green Electricity from Wind for German Production Sites

    By Nat Schaefer

    Gerresheimer, the innovative system and solution provider and global partner to the pharma, biotech and cosmetics industries, has signed a long-term electricity supply agreement with PNE, an international project planning company and wind turbine operator. The power purchase agreement (PPA), which covers around 35GWh of wind power per year, will enable Gerresheimer to reduce its CO₂ emissions by around 18,000t* each year starting in 2024.

  • 09 Nov 2023
«‹34567›»